brain_esni.jpg

News

  • Regeneration

    November 16-18, 2017, Milan Italy

    Read more ...  
  • 14th ISNI Congress & 2nd GSNI Pre-Course

    August 27-31, 2018 - Brisbane, Australia

    Read more ...  

Manuel

MD, PhD
Neurologist. Neurology / Neuroimmunology
Department. Vall d'Hebron University Hospital
Director of Laboratory. MS Centre of Catalonia
Vall d'Hebron University Hospital
mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

EDUCATION
Facultat de Medicina, Universitat de Barcelona - MD - 1990 - Medicine and Surgery
Residence in Neurology - Neurologist - 1995 - Neurology
Facultat de Medicina, Universitat Autonoma de Barcelona - PhD - 2013 - Medicine

RESEARCH AND PROFESSIONAL EXPERIENCE
2015 – Coordinator of the BioMSeu (European Consortium for CSF Biomarker Research; http://www.biomseu.com)
2013 – Coordinator of Neurosciences. Fundació Institut de Recerca Hospital Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain
2013 – Member of the Internal Scientific Committee. Fundació Institut de Recerca Hospital Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain
2008 – Senior neurologist. Neurology / Neuroimmunology Department, Vall d’Hebron University Hospital. Barcelona, Spain
2004 – Director of Laboratory. MS Centre of Catalonia, Neurology / Neuroimmunology Department, Vall d’Hebron University Hospital. Barcelona, Spain
1999 – 2003 Research Neurologist. Vall d’Hebron University Hospital. Barcelona, Spain
1996 – 1998 Research fellowship in Neuroimmunology, Brigham and Women's Hospital - Center for Neurologic Diseases, Harvard Medical School, Boston (US)
1992 – 1995 Neurology Resident (MIR Program), Vall d’Hebron University Hospital. Barcelona, Spain

PUBLICATIONS
1. Comabella M, Cantó E, Nurtdinov R, Río J, Villar LM, Picón C, Castilló J, Fissolo N, Aymerich X, Auger C, Rovira A, Montalban X. MRI phenotypes with high neurodegeneration are associated with peripheral blood B-cell changes. Hum Mol Genet. 2016 Jan 15;25(2):308-16.
2. Borràs E, Cantó E, Choi M, Maria Villar L, Álvarez-Cermeño JC, Chiva C, Montalban X, Vitek O, Comabella M, Sabidó E. Protein-Based Classifier to Predict Conversion from Clinically Isolated Syndrome to Multiple Sclerosis. Mol Cell Proteomics. 2016 Jan;15(1):318-28.
3. Cantó E, Tintoré M, Villar LM, Costa C, Nurtdinov R, Álvarez-Cermeño JC, Arrambide G, Reverter F, Deisenhammer F, Hegen H, Khademi M, Olsson T, Tumani H, Rodríguez-Martín E, Piehl F, Bartos A, Zimova D, Kotoucova J, Kuhle J, Kappos L, García-Merino JA, Sánchez AJ, Saiz A, Blanco Y, Hintzen R, Jafari N, Brassat D, Lauda F, Roesler R, Rejdak K, Papuc E, de Andrés C, Rauch S, Khalil M, Enzinger C, Galimberti D, Scarpini E, Teunissen C, Sánchez A, Rovira A, Montalban X, Comabella M. Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. Brain. 2015 Apr;138(Pt 4):918-31.
4. Malhotra S, Río J, Urcelay E, Nurtdinov R, Bustamante MF, Fernández O, Oliver B, Zettl U, Brassat D, Killestein J, Lechner-Scott J, Drulovic J, Chan A, Martinelli-Boneschi F, García-Merino A, Montalban X, Comabella M. NLRP3 inflammasome is associated with the response to IFN-β in patients with multiple sclerosis. Brain. 2015 Mar;138(Pt 3):644-52.
5. Cantó E, Espejo C, Costa C, Montalban X, Comabella M. Breast regression protein-39 is not required for experimental autoimmune encephalomyelitis induction. Clin Immunol. 2015 Oct;160(2):133-41.
6. Cantó E, Tintoré M, Villar LM, Borrás E, Alvarez-Cermeño JC, Chiva C, Sabidó E, Rovira A, Montalban X, Comabella M. Validation of semaphorin 7A and ala-β-his-dipeptidase as biomarkers associated with the conversion from clinically isolated syndrome to multiple sclerosis. J Neuroinflammation. 2014 Nov 13;11:181.
7. Liu Y, Carlsson R, Comabella M, Wang J, Kosicki M, Carrion B, Hasan M, Wu X, Montalban X, Dziegiel MH, Sellebjerg F, Sørensen PS, Helin K, Issazadeh-Navikas S. FoxA1 directs the lineage and immunosuppressive properties of a novel regulatory T cell population in EAE and MS. Nat Med. 2014 Mar;20(3):272-82.
8. Comabella M, Montalban X. Body fluid biomarkers in multiple sclerosis. Lancet Neurol. 2014 Jan;13(1):113-26.
9. Comabella M, Caminero AB, Malhotra S, Agulló L, Fernández O, Reverter F, Vandenbroeck K, Rodríguez-Antigüedad A, Matesanz F, Izquierdo G, Urcelay E, López-Larios A, Sánchez A, Otero S, Tintoré M, Montalban X. TNFRSF1A polymorphisms rs1800693 and rs4149584 in patients with multiple sclerosis. Neurology. 2013 May 28;80(22):2010-6.
10. Fissolo N, Costa C, Nurtdinov RN, Bustamante MF, Llombart V, Mansilla MJ, Espejo C, Montalban X, Comabella M. Treatment with MOG-DNA vaccines induces CD4+CD25+FoxP3+ regulatory T cells and up-regulates genes with neuroprotective functions in experimental autoimmune encephalomyelitis. J Neuroinflammation. 2012 Jun 22;9:139.
11. Chan A, Pirmohamed M, Comabella M. Pharmacogenomics in neurology: current state and future steps. Ann Neurol. 2011 Nov;70(5):684-97.
12. Bustamante MF, Fissolo N, Río J, Espejo C, Costa C, Mansilla MJ, Lizasoain I, Moro MA, Carmen Edo M, Montalban X, Comabella M. Implication of the Toll-like receptor 4 pathway in the response to interferon-β in multiple sclerosis. Ann Neurol. 2011 Oct;70(4):634-45.
13. Comabella M, Fernández M, Martin R, Rivera-Vallvé S, Borrás E, Chiva C, Julià E, Rovira A, Cantó E, Alvarez-Cermeño JC, Villar LM, Tintoré M, Montalban X. Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain. 2010 Apr;133(Pt 4):1082-93.
14. Lünemann JD, Tintoré M, Messmer B, Strowig T, Rovira A, Perkal H, Caballero E, Münz C, Montalban X, Comabella M. Elevated Epstein-Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis. Ann Neurol. 2010 Feb;67(2):159-69.
15. Camiña-Tato M, Morcillo-Suárez C, Bustamante MF, Ortega I, Navarro A, Muntasell A, López-Botet M, Sánchez A, Carmona P, Julià E, Tortola MT, Audí L, Oksenberg JR, Martin R, Montalban X, Comabella M. Gender-associated differences of perforin polymorphisms in the susceptibility to multiple sclerosis. J Immunol. 2010 Nov 1;185(9):5392-404.
16. Comabella M, Lünemann JD, Río J, Sánchez A, López C, Julià E, Fernández M, Nonell L, Camiña-Tato M, Deisenhammer F, Caballero E, Tortola MT, Prinz M, Montalban X, Martin R. A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. Brain. 2009 Dec;132(Pt 12):3353-65.
17. Comabella M, Craig DW, Morcillo-Suárez C, Río J, Navarro A, Fernández M, Martin R, Montalban X. Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis. Arch Neurol. 2009 Aug;66(8):972-8.

Joomla Template by Joomla51.com